| Title: | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults with Treatment Resistant Depression |
| Sponsor: | Navitor Pharmaceuticals, Inc. |
| Study Phase: | 2 |
| Study Sites: | Approximately 35 sites are planned in the US. |
| Indication: | Treatment Resistant Depression (TRD) |
| Primary Objective: | To evaluate the efficacy of NV-5138 compared to placebo when administered to adults with TRD. |
